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ABSTRACT
The biocatalyzed production of building blocks for synthesizing drugs is a very attractive
research field, because of the sustainability introduced in a synthetic schedule when chemical
steps are substituted by biocatalyzed protocols. In this article, we will show how different anti-
diabetic drugs, for treating diabetes mellitus Type 1 and Type 2, can be more efficiently and
effectively synthetized with the help of different types of biocatalysts. The huge overall drug
market for these drugs, as well as the great number of people suffering from diabetes (the
prevalence of all types of diabetes is growing), makes this topic attractive enough to focus on
more efficient synthetic protocols for preparing antidiabetic drugs. Examples covering biocata-
lyzed synthesis of insulin analogues, sensitizers (PPAR agonists), secretagogues (GLP-1 analogues,
GPR119 agonists) and enzyme inhibitors (a-glucosidase inhibitors, DPP4-inhibitors, SGLT-2 inhibi-
tors and 11b-HSD1 inhibitors) will be presented.
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Introduction
Diabetes mellitus (DM) is a disorder of metabolic
homeostasis, showing hyperglycaemia and altered lipid
metabolism caused by dysfunction of pancreatic islets,
which do not produce enough insulin (a hormone that
regulates blood sugar or glucose), or rather caused
when the body cannot effectively use the insulin it
produces (World Health Organization 2016). According
to this, there are three main types of DM (American
Diabetes Association 2014; Ramachandran et al. 2017);
thus, Type 1DM results from the inherent pancreas’s
failure to produce enough insulin, being this type for-
merly known as “insulin-dependent diabetes mellitus”
(IDDM) or “juvenile diabetes”. Conversely, Type 2DM is
caused by insulin resistance, and it was previously
referred to as “non-insulin-dependent diabetes
mellitus” (NIDDM) or “adult-onset diabetes”. Finally,
gestational diabetes is the third main form and occurs
when pregnant women without a previous history of
diabetes develop high blood sugar levels.
DM is one of the most common chronic conditions
in nearly all countries. In 2014, the International
Diabetes Federation (IDF) assessed that 8.2% of adults
between 20 and 79 (around 387 million people) were
living with diabetes, an increase compared to 382 mil-
lion people in 2013 (Fernandes et al. 2016).
Clearly, the prevalence of all types of diabetes is grow-
ing, particularly Type 2DM; this can be seen from
2014 data (422 million (World Health Organization
2016; Zhou et al. 2016)) or 2015 (415 million, 1 out of
11 adults (International Diabetes Federation 2015)),
while the number of people affected by DM is esti-
mated to increase up to 439 million people in 2030,
reaching 592 million people by 2035 (World Health
Organization 2016) and 642 in 2040, which means 1
out of 10 adults (International Diabetes Federation
2015; Ali et al. 2017).
Obviously, DM is a major cause of morbidity and
mortality in many countries, although 80% of people
with diabetes live in low- and middle-income countries
(International Diabetes Federation 2015; World Health
Organization 2016); globally, it caused around 5.0 mil-
lion deaths in 2013 (IDF Diabetes Atlas Group 2015)
and a similar number in 2015 (International Diabetes
Federation 2015). Considering global costs of DM, it
has been reported that at least $612 billion were spent
globally on diabetes in 2014, representing 11% of all
global health expenditures. This represents an increase
of 12% compared to the data published in 2013 ($548
billion), due to increases in the total number of people
with diabetes (Fernandes et al. 2016). In 2015, 12%
of global health expenditure (around $673 billion)
was dedicated to diabetes treatment and related
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complications, and the majority of countries spent
between 5% and 20% of their total health expenditure
on DM (International Diabetes Federation 2015;
Williams 2016).
Therefore, the world market for diabetes drugs is
really huge, $35.6 billion in 2012 (Visiongain 2013),
growing up to 51.1 billion in 2015 (Global Market
Insight, Inc. 2016), and it is estimated to reach $55.3
billion in 2017 (Visiongain 2013) and more than
double, $116.1 billion, by 2023 (Global Market Insight,
Inc. 2016). While Type 1DM can only be treated with
insulin or synthetic insulin analogues (Freeland and
Farber 2016; Zaykov et al. 2016), for the treatment of
Type 2DM either insulin or other types of mostly oral
drugs, either as a single API or a combination of them,
can be used (Freeland and Farber 2015; Kokil et al.
2015; Gaitonde et al. 2016)
Taking into consideration all of these data, it is cer-
tainly understandable that the development of effi-
cient and sustainable methodologies for synthesizing
antidiabetic drugs is highly desirable. For this purpose,
the use of biocatalyzed protocols is increasingly
becoming recognized as a very important part inside
Green Chemistry (Malhotra et al. 2015; Sheldon 2016),
because those synthetic routes mediated by enzymes
or cells are generally conducted under mild reaction
conditions, at ambient temperature and can use water
as reaction medium in many cases (Hoyos et al. 2013);
moreover, their high selectivity avoids the need of
functional group activation and protection/deprotec-
tion steps usually required in traditional organic
synthesis. Thus, biocatalysis provides processes which
are shorter, produce less waste (generally measured
using E-factor value, ratio between the kilograms of
waste to the kilograms of desired product (Sheldon
2017)) and reduce manufacturing costs and environ-
mental impact. These features are even more signifi-
cant in drug synthesis, because it is well known that
Pharma Industry produces a great amount of waste, so
that implementing biocatalyzed protocols is increas-
ingly being employed (Hoyos et al. 2014; Patel 2016a,
2016b, 2016c).
To focus this article, we will comment some exam-
ples illustrating the use of chemoenzymatic protocols
for the sustainable synthesis of antidiabetic drugs. For
this purpose, first we will mention some cases in
which biocatalysis has been useful for the preparation
of insulin analogues (treatment of DM Type 1 and 2),
and subsequently we will focus in the chemoenzy-
matic synthesis of drugs specially designed for the
treatment of Type 2DM.
Insulin and insulin analogues
Semisynthetic human insulin was commercially devel-
oped in the 1970s by Novo Nordisk A/S, starting from
porcine insulin, by substituting the B-30 alanine resi-
due of porcine insulin with a threonine residue
(Markussen 1981; Andresen and Balschmidt 1982), as
shown in Figure 1.
For these biotransformations, five steps were
required (Barfoed 1987): insulin was first extracted
from frozen porcine pancreas glands. In a second step,
of the purified porcine insulin was converted into
human insulin in a medium that contains only a small
amount of water and trypsin and a large quantity of
organic solvent and threonine ester. Subsequently,
trypsin hydrolyzed insulin at LysB29-AlaB30, while at the
same time catalyzed the reverse reaction in which the
threonine ester displaced alanine from position B30 in
the insulin molecule. This transpeptidation of porcine
insulin to human insulin was optimized to 97% yield
using soluble trypsin (Morihara et al. 1979). This was
followed by chromatographic purification to reduce
measurable levels of proinsulin and remove the other
reagents, pharmaceutical formulation and distribution
into the market. Finally, the product was formulated
and then filled under sterile conditions, packaged, and
distributed. Transpeptidation was also catalyzed by
immobilized trypsin, although the yield was lower
(80%) (Ueno and Morihara 1989). Another protease,
from Achromobacter lyticus, was also found to be com-
pletely specific in the hydrolysis of LysB29-AlaB30 and
the subsequent condensation con H-Thr-OBut
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212Figure 1. Semisynthesis of human insulin from porcine insulin by trypsin-catalyzed transpeptidation.
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(Morihara et al. 1980; Morihara and Ueno 1991). Also,
the use of carboxypeptidase A for the same procedure
was described (Andresen et al. 1983).
Human insulin was the first animal protein to be
made in bacteria in a sequence identical to that of the
human pancreatic peptide, as early as 1978 by
Genentech (lab scale) and Eli Lilly and Co. (scale-up)
(Johnson 1983), working together to achieve the
expression of recombinant human insulin in
Escherichia coli K-12 using genes for the insulin A and
B chains; thus, each insulin chain was produced as a
b-galactosidase fusion protein in separate fermenta-
tions using E. coli cells transformed with plasmids con-
taining either the A or B insulin peptide sequence. The
intracellular products, once removed from the inclu-
sion bodies, were chemically cleavage by CNBr at the
Met residue between the b-gal and the A or B chains,
purified, suffered an oxidative sulfitolysis and chem-
ically linked to afford crude insulin. A final purification
process led to the first production of recombinant
human insulin, approved by drug regulatory agencies
in 1982 (Ladisch and Kohlmann 1992).
After this pioneering work, some other strategies
were developed using recombinant microorganisms
that produce intact proinsulin instead of the A or B
chains separately. For instance, Novo used
Saccharomyces cerevisiae to secrete insulin as a single-
chain insulin precursor, in which amino acid 30 of the
B chain of insulin was connected to amino acid 1 of
the A chain by a peptide (Chain C), as shown in
Figure 2. Two enzymatic cleavages, the first one cata-
lyzed by trypsin leading to the removal of most of
the C chain, and the second one catalyzed by
caboxypeptidase to delete two Arg residues from
BThr30, yield the human insulin (Thim et al. 1986;
Ladisch and Kohlmann 1992).
Since those innovative methods, many other proto-
cols based on genetic engineering have been devel-
oped, and nowadays recombinant human insulin is
mainly produced either in E. coli or S. cerevisiae,
although several other alternate yeast strains have
been explored for insulin production, as well as mam-
malian cells, transgenic animals or plant expression
systems have been also employed as a host for large-
scale production of recombinant insulin (Walsh 2005;
Baeshen et al. 2014).
On the other hand, by using recombinant DNA
technology different insulin analogues have been syn-
thesized. This term refers to an altered form of insulin,
different from any occurring in nature, still available to
the human body for performing the same action as
human insulin in terms of glycaemic control, but dis-
playing improved ADME (absorption, distribution,
metabolism, and excretion) characteristics (Zaykov
et al. 2016). Officially, the U.S. Food and Drug
Administration (FDA) refers to these as “insulin recep-
tor ligands”, although they are more commonly named
as insulin analogues, which can be classified into two
main classes:
a. those that are more readily absorbed from the
injection site and therefore act faster than natural
insulin injected subcutaneously, intended to sup-
ply the bolus level of insulin needed at mealtime
(prandial insulin)
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b. those that are released slowly over a period of
between 8 and 24 h, intended to supply the basal
level of insulin during the day and particularly at
night time (basal insulin).
Among fast-action analogues, Eli Lilly and Co. devel-
oped and marketed in 1996 Humalog, the first rapid-
acting insulin analogue (insulin lispro rDNA). This
analogue was engineered through recombinant DNA
technology, so that the penultimate lysine and proline
residues on the C-terminal end of the B-chain
(ProB28LysB29) were reversed (Figure 3). This modifica-
tion did not alter the insulin receptor binding, but
blocked the formation of insulin dimers and hexamers
(Howey et al. 1994; Torlone et al. 1994), therefore
allowing larger amounts of active monomeric insulin
to be available for postprandial (after meal) injections
(Anderson et al. 1997). The second entry in this class,
insulin aspart (Novolog, Novo Nordisk), was first mar-
keted in 2000 and utilizes an Asp at position B28
(Brange et al. 1988; Home et al. 1998, 2000). The most
recent rapid-acting analogue, insulin glulisine (Apidra,
Sanofi), was marketed in 2006 and is based on
replacements of LysB29 with Glu and of AsnB3 with Lys
(Becker et al. 2005; Dreyer et al. 2005; Becker and Frick
2008).
Considering those analogues intended to control
basal insulin levels, insulin glargine (Lantus, Sanofi),
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launched in 2001, uses a shift in isoelectric point
(achieved through two additional Arg residues at posi-
tions B31 and B32) in order to dramatically lower solu-
bility at physiological pH, rendering the insulin far less
soluble at the injection site. This results in an
extended time–action profile as the analogue slowly
re-solubilizes (Rosenstock et al. 2001). Additionally, a
Gly residue is introduced at position A21 to maintain
chemical stability in the aqueous, acidic formulation.
Another different tactic consists in attaching a long-
chain fatty acid with the purpose of slowing adsorp-
tion and facilitating extended plasma circulation
through non-covalent albumin binding. This strategy
was reported by Eli Lilly with insulin lipidated at
LysB29 with palmitic acid (W99-S-32) (Myers et al.
1995) and by Novo Nordisk with LysB29-myristyl
desB30-insulin, launched in 2006 under the name of
insulin detemir (Levemir) (Havelund et al. 2004;
Hermansen et al. 2006). Very recently, two new basal
insulin analogues completed Phase III trials (Pettus
et al. 2016): insulin degludec (Tresiba, Novo Nordisk), a
des-B30 human insulin that is uniquely fatty-acylated
at LysB29 with hexadecanedioic acid via gamma-L-glu-
tamyl spacer (Wang et al. 2012; Gough et al. 2013),
which have been recently approved by FDA in the
USA, and insulin peglispro (Ly2605541), derived by
covalent attachment of a linear 20 kD polyethylene
glycol (PEG) polymer to the LysB28 side-chain in insu-
lin lispro (Henry et al. 2014).
Generally speaking, the use of synthetic biology for
creating cell factories is the methodology used at
industrial scale in the preparation of these insulin ana-
logues (Baeshen, Baeshen et al. 2014; Sanchez-Garcia
et al. 2016). For sure, the improvement of metabolic
pathways for increasing their production can be classi-
fied as sequential (or cascade) biocatalytical processes,
and not many examples of protease modifications of
precursors leading to insulin analogues, which can be
sensu stricto considered biotransformations, can be
found in literature (Bogsnes et al. 2003; Habermann
and Zocher 2008). Anyway, ample research is being
carried out in the development of new analogues of
insulin (Freeland and Farber 2016; Pettus et al. 2016;
Zaykov et al. 2016; Sherr et al. 2017) and new and
faster formulations (Sherr et al. 2017), because there is
little to no alternatives to brand-named analogue insu-
lin and non-analogue human alternatives for treating
both types of DM in low- and middle-income countries
(Kaplan and Beall 2017).
Other antidiabetic drugs
Inside this category we will include:
a. drugs that increase the sensitivity of target organs
to insulin, called sensitizers
b. agents that increase the amount of insulin
secreted by the pancreas, known as
secretagogues
c. agents that decrease the rate at which glucose is
absorbed from the gastrointestinal tract.
d. enzyme inhibitors
We will show now different examples of biocata-
lyzed synthesis of some of these compounds. The use
of biocatalysts is especially adequate for the stereo-
selective synthesis of those drugs possessing at least
one stereogenic centre.
Sensitizers
Drugs belonging to this category are biguanides (such
as metformin, 1), thiazolidinediones (TZDs, also named
glitazones, 2), and glitazares 3), shown in Figure 4. The
first class is represented by metformin, the first-line
medication for the treatment of Type 2DM (Maruthur
et al. 2016; Wise 2016), which is synthetized only by
classical chemical methods, so that we will mention
the other two classes, glitazones and glitazars.
Peroxisome proliferator-activated receptors (PPAR)
agonists
The PPARs are ligand-dependent transcription factors.
The three mammalian PPARs (a, b/d and c)
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(Nevin et al. 2011; Wright et al. 2014) are crucial regu-
lators of fatty acid and lipoprotein metabolism, glu-
cose homeostasis, cellular proliferation/differentiation
and the immune response. Therefore, PPARs are key
targets in the treatment of metabolic disorders such as
insulin resistance and Type 2DM; furthermore, PPARs
are also involved in chronic inflammatory diseases
such as atherosclerosis, arthritis, chronic pulmonary
inflammation, pancreatitis, inflammatory bowel dis-
ease, psoriasis, blood pressure regulation, neuroinflam-
mation, nerve-cell protection, inflammatory pain
reduction, and hypothalamic control of metabolism
(Menendez-Gutierrez et al. 2012). However, PPAR-c,
which is expressed in adipose tissue, lower intestine,
and cells involved in immunity, is the most extensively
investigated PPAR, while PPAR-d, which regulates
several metabolic processes, has also been investi-
gated for the development of new drugs for treating
DM (Wright et al. 2014).
There are three marketed TZDs, acting as PPAR-c
agonist: pioglitazone (2a, ActosTM or GlustinTM, Takeda
Pharmas USA and Eli Lilly), rosiglitazone (2b,
AvandiaTM, GlaxoSmithKline), and lobeglitazone (2c,
DuvieTM, Chong Kun Dang), whose chemical structures
are shown in Figure 5. Common for the chemical
structure of TZDs compounds is the chiral centre at
the C-5 of the ring, prone to racemization at physio-
logical pH (Welch et al. 2003; Rippley et al. 2007;
Jamali et al. 2008), as also shown in Figure 5.
Consequently, in animal models, the individual enan-
tiomers and racemates of glitazones appear to show
equivalent activity as antidiabetic agents, so that most
synthetic methodologies are conducted following con-
ventional chemical steps (Ortiz and Sansinenea 2011).
However, Parks et al. (1998), through the in vitro
analysis of rosiglitazone enantiomers in a PPARc-
binding assay, suggested that the (S)-isomer is the
main responsible for the antidiabetic activity, and a
similar behaviour of the (S)-eutomer was described for
rivoglitazone, another glitazone which failed to reach
the drug market (Izumi et al. 2013). On the other
hand, pioglitazone is currently undergoing clinical tri-
als for treatment of Alzheimer’s disease (AD): when
mice were dosed with racaemic pioglitazone, the con-
centration of (R)-(þ)-pioglitazone was 46.6% higher
than that of (S)-()-pioglitazone in brain tissue and
67.7% lower than that of (S)-pioglitazone in plasma,
and dosing mice with pure (R)-pioglitazone led to a
76% increase in brain exposure levels compared to
those from an equivalent dose of racaemic
pioglitazone (Chang et al. 2015). Furthermore, pure
(R)-pioglitazone was also shown to have comparable
amyloid-lowering capabilities to the racaemic pioglita-
zone in an in vitro AD model, so that dosing with (R)-
pioglitazone instead of the racaemic mixture may
result in higher levels of brain exposure to
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pioglitazone, thus potentially improving the develop-
ment of pioglitazone treatment of AD.
Thus, it is possible to find in literature some exam-
ples of the resolution of both enantiomer of
glitazones, either through their derivatization to dia-
stereoisomers (Sohda et al. 1984; Gahafu et al. 2010;
van Niel et al. 2011a, 2011b) or by preparative chiral
HPLC (Calixto and Bonato 2013). On the other hand,
the first example of stereoselective biocatalytic synthe-
sis was described by researchers at SmithKline
Beecham by means of the bioreduction of the precur-
sor benzylidine compound 4 (Figure 6), catalyzed by
whole cells from red yeast Rhodotorula rubra CBS 6469
(Cantello et al. 1994).
These authors observed that the bioreduction pro-
ceeded at basic pH values with a high degree of
stereoselectivity, but that the product was undergoing
racemization, the rate of racemization being slower
than the rate of product formation under these condi-
tions. Thus, the biotransformation was carried out
under acidic pH conditions. Over a 4 h reaction at pH
3.75, the product was found to be of >98% enantio-
meric purity. These authors also described the use of
alginate-entrapped immobilized cells for performing
the bioreduction (Cantello et al. 1994), which was fur-
ther scaled-up by some other scientists of the same
company (Heath et al. 1997).
On the other hand, PPAR-a agonists serve as cellu-
lar receptor for fibrates, a class of drugs used in the
treatment of dyslipidaemia, and also used for the
treatment of vascular complications associated with
Type 2DM (Verges 2004; Steiner 2007). These fibrates
possess a common chemical structure (2-methyl-2-ary-
loxypropionic acids or esters), not displaying any chiral
centre. In an attempt to obtain an enantiopure PPAR-a
agonist, Astra Zeneca synthesized AZD 4619 (Figure 7,
(S)-6), an a agonist, by means of an enzymatic
dynamic kinetic resolution (DKR) of the corresponding
racaemic thioester, using an organic base to promote
the racemization (Brown et al. 2006), as shown
in Figure 7.
The thioester rac-5 was resolved with Pseudomonas
cepacia lipase in the presence of a tert-amine base, tri-
octylamine. The desired acid (S)-6 is stable, and
residual (R)-thioester was racemized by deprotonation
and reprotonation catalyzed by the organic base,
which cannot make a similar undesired racemization
step of (S)-6, because the a protons of the carboxylate
product are not acidic enough to be deprotonated by
tert-amine bases. Although this process was scaled to
grams, AZD 4619 was discontinued because of hepato-
toxicity problems detected in Phase I (Thulin et al.
2008). Similarly, the resolution of the racaemic alpha-
chloro thioester intermediate 7 has been described
using the same strategy, shown in Figure 8 (Dow et al.
2012). Remarkably, the use of a protease instead of a
lipase allowed the synthesis of the antipode (R)-8,
although with a lower ee (90% with Savinase versus
98% with lipase).
Glitazars (Figure 9) are dual PPAR a/c agonists
that improve the lipid profile and exert an antidia-
betic action, similar to a combination of a fibrate
and a thiazolidinedione, so that they are
considered as “two drugs in one” (Wilding 2012).
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Figure 6. Biocatalyzed synthesis of (R)-(þ)-rosiglitazone.
Figure 7. DKR process to synthesize AZD 4619.
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Figure 8. DKR process to synthesize a precursor of AZD 4619.
Figure 9. Some glitazars.
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